Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Andrx Generic Zyban/Wellbutrin SR To Be Approved Mid-Year After Patent Win

Executive Summary

Andrx' generic version of GlaxoSmithKline's Wellbutrin SR and Zyban (bupropion sustained release) is expected to be approved by mid-year following a Feb. 28 patent ruling

You may also be interested in...



GSK vs. Andrx Wellbutrin SR Appeal Turns On Role Of Excipient

GlaxoSmithKline's Wellbutrin SR and Zyban patents do not cover the low-density form of the excipient HPMC used in Andrx' ANDA product, the generic company argued during a federal circuit appeals court hearing in Washington, D.C. Dec. 2

GSK vs. Andrx Wellbutrin SR Appeal Turns On Role Of Excipient

GlaxoSmithKline's Wellbutrin SR and Zyban patents do not cover the low-density form of the excipient HPMC used in Andrx' ANDA product, the generic company argued during a federal circuit appeals court hearing in Washington, D.C. Dec. 2

Naprelan Generic Exclusivity Settled; Andrx Sees Three Near-Term Launches

SkyePharma has waived its 180-day exclusivity for a generic version of Elan's Naprelan (naproxen), clearing the way for approval of Andrx' generic version of the product, Andrx says

UsernamePublicRestriction

Register

PS039390

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel